LONDON--GlaxoSmithKline PLC (GSK), a research-based pharmaceutical and healthcare company, said Friday it has completed its acquisition of Human Genome Sciences (HGSI) for 3.6 billion dollars on an equity basis, or $3 billion net of cash and debt.
-All outstanding shares of HGS were acquired for $14.25 per share in cash.
-Subsequent offering period for GSK's tender offer for HGS shares expired at 2100 GMT, on Aug. 2.
-Glaxo shares closed in London Thursday at 1487 pence valuing the company at 74.16 billion pounds.
-Write to Ian Walker at firstname.lastname@example.org
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
(END) Dow Jones Newswires
August 03, 2012 02:45 ET (06:45 GMT)
Copyright (c) 2012 Dow Jones & Company, Inc.